AAVantage® AAV Capsid Library Products

Get in Touch

Ways to Collaborate

Using AAVantage®-Novel AAV Capsid Evolution and Screening Platform , we have designed and validated several capsid libraries, and developed novel AAV capsid variants for retina and liver-directed human disease treatment. 

Get in Touch

Products

  • 01

    Novel AAV capsid for retinal pigmented epithelium (RPE) targeting via intravitreal injection

    Retina-targeting AAV capsid variants

    • High tissue specificity for RPE
    • Intravitreal delivery
    • Selection in NHP
    • Transduction efficiency 5x better than AAV2-7m8
  • 02

    Novel immune-evading AAV capsids for liver targeting

    Liver-targeting AAV capsid variants with exceptional immune evasion properties

    • High specificity for human hepatocytes
    • Better transduction efficiency than the current best variant AAV3B-V04
    • Exceptional evasion of preexisting neutralizing antibodies
  • 03

    Capsid libraries

    Retina-targeting AAV capsid variants

    • 3 libraries based on human serotypes
      High transduction efficiency and production yield
    • 2 library based on a non-primate AAV
      Evasion of human preexisting neutralizing antibodies
    • 1 library based on a non-AAV parvovirus
      Large capacity of genome size (up to 6.1 kb)

Flexible Business Models

Porton Advanced is open to explore R&D partnerships on projects of mutual interest.

Clients & Partners

View More